RhumbLine Advisers’s Cellectis CLLS Stock Holding History

RhumbLine Advisers’s Portfolio CLLS Stock Details CLLS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$47.8K	Buy	15,085 +1,742	+13%	+$6.68K	﹤0.01%	3596
2025 Q4	$64.6K	Buy	13,343 +11,888	+817%	+$49.7K	﹤0.01%	3585
2025 Q3	$4.15K	Sell	1,455 -450	-24%	-$1.17K	﹤0.01%	3927
2025 Q2	$2.88K	Sell	1,905 -210	-10%	-$303	﹤0.01%	3964
2025 Q1	$2.62K	Hold	2,115	–	–	﹤0.01%	3964
2024 Q4	$3.81K	Sell	2,115 -1,740	-45%	-$3.25K	﹤0.01%	3985
2024 Q3	$8.25K	Hold	3,855	–	–	﹤0.01%	3915
2024 Q2	$7.21K	Hold	3,855	–	–	﹤0.01%	4024
2024 Q1	$10.2K	Hold	3,855	–	–	﹤0.01%	3867
2023 Q4	$11.9K	Buy	3,855 +885	+30%	+$2.1K	﹤0.01%	3838
2023 Q3	$4.69K	Hold	2,970	–	–	﹤0.01%	3989
2023 Q2	$5.85K	Buy	+2,970	New	+$5.69K	﹤0.01%	4058

Other funds holding CLLS

BGI

B Group Inc Dallas, Texas $135M AUM 80% 1-Year Est. Return

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

LFCM

Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

NAMI

Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

RhumbLine Advisers's CLLS Position: Q1 2026 in Review

RhumbLine Advisers increased its Cellectis (CLLS) stake by 13% in Q1 2026, buying an estimated $6.68K and bringing the position to 15,085 shares worth $47.8K. The position accounts for ﹤0.01% of the portfolio, ranked #3596.

RhumbLine Advisers first reported a position in CLLS in Q2 2023 and has held it in 12 quarters since. The position peaked at $64.6K in Q4 2025. 32 funds tracked by Wall St. Rank hold CLLS as of Q1 2026.

RhumbLine Advisers held 15,085 shares of Cellectis worth $47.8K as of Q1 2026.
RhumbLine Advisers bought 1,742 Cellectis shares in Q1 2026, an estimated $6.68K.
Cellectis made up ﹤0.01% of RhumbLine Advisers's portfolio in Q1 2026, its #3596 holding.
RhumbLine Advisers first reported a position in Cellectis in Q2 2023 and has held it in 12 quarters since.
RhumbLine Advisers's Cellectis position peaked at $64.6K in Q4 2025.
32 funds tracked by Wall St. Rank held Cellectis as of Q1 2026.

Based on RhumbLine Advisers's 13F filing for Q1 2026, filed 12 May 2026.